Department of Radiation Oncology of the University Medical Center Mannheim, University of Heidelberg.
Strahlenther Onkol. 2010 May;186(5):280-8. doi: 10.1007/s00066-010-2071-z. Epub 2010 Apr 26.
Volumetric modulated arc therapy (VMAT) has the potential to deliver dose distributions comparable to the established intensity-modulated radiotherapy techniques for a multitude of target paradigms. Prior to implementing VMAT into their clinical routine in December 2008, the authors evaluated the dose calculation/delivery accuracy of 24 sample VMAT plans (prostate and anal cancer target paradigms) with film and ionization dosimetry. After the start of the clinical program, in vivo measurements with a rectal probe were performed.
The VMAT plans were generated by the treatment-planning system (TPS) ERGO++ (Elekta, Crawley, UK) and transferred to a phantom. Film dosimetry was performed with Kodak EDR2 films, and evaluated with dose profiles and gamma-index analysis. Appropriate ionization chambers were used for absolute dose measurements in the phantom and for in vivo measurements. The ionization chamber was used with localization of the measurement volume based on positioning cone-beam computed tomography.
Plans were transferred from ERGO++ to the record and verify (R&V) system/linear accelerator (linac). The absolute dose deviations recorded with the ionization chamber were 1.74% +/- 1.62% across both indications. The gamma-index analysis of the film dosimetry showed no deviation > 3%/3 mm in the high-dose region. On in vivo measurements, a deviation between calculation and measurement of 2.09% +/- 2.4% was recorded, when the chamber was successfully positioned in the high-dose region.
VMAT plans can be planned and treated reproducibly in high quality after the commissioning of the complete delivery chain consisting of TPS, R&V system and linac. The results of the individual plan verification meet the commonly accepted requirements. The first in vivo measurements confirm the reproducible precision of the delivered dose during clinical treatments.
容积旋转调强放疗(VMAT)有可能为多种靶区提供与既定强度调制放疗技术相媲美的剂量分布。在 2008 年 12 月将 VMAT 引入临床常规之前,作者使用胶片和电离室剂量学对 24 个样本 VMAT 计划(前列腺和肛门癌靶区)进行了剂量计算/传递准确性评估。在临床项目开始后,使用直肠探头进行了体内测量。
VMAT 计划由治疗计划系统(TPS)ERGO++(Elekta,英国克劳利)生成,并传输到体模中。胶片剂量学使用柯达 EDR2 胶片进行,并通过剂量分布和伽马指数分析进行评估。适当的电离室用于在体模中进行绝对剂量测量和体内测量。使用电离室进行基于定位锥形束 CT 的测量体积定位。
计划从 ERGO++传输到记录和验证(R&V)系统/直线加速器(linac)。在两种情况下,电离室记录的绝对剂量偏差为 1.74% +/- 1.62%。胶片剂量学的伽马指数分析显示,高剂量区域无偏差> 3%/3mm。在体内测量中,当腔成功定位在高剂量区域时,记录到计算与测量之间的偏差为 2.09% +/- 2.4%。
在完成由 TPS、R&V 系统和直线加速器组成的完整传输链的调试后,VMAT 计划可以高质量地进行规划和治疗。各个计划验证的结果符合普遍接受的要求。首次体内测量证实了在临床治疗过程中交付剂量的可重复性精度。